NCT01927861 - Investigating the Long-term Efficacy and Safety of Two Doses of NN-220 (Somatropin) in Short Stature Due to Noonan Syndrome | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 19, 2013

Primary Completion Date

July 12, 2018

Study Completion Date

July 12, 2018

Conditions

Genetic DisorderNoonan Syndrome

Interventions

DRUG

somatropin

Administered subcutaneously (s.c., under the skin) in a daily regimen for at least 104 weeks. Subject will be offered to continue treatment for another 104 weeks.

Trial Locations (27)

078-8510

Novo Nordisk Investigational Site, Asahikawa, Hokkaido

812-8582

Novo Nordisk Investigational Site, Fukuoka

830-0011

Novo Nordisk Investigational Site, Fukuoka

350 0495

Novo Nordisk Investigational Site, Iruma-gun, Saitama

216-8511

Novo Nordisk Investigational Site, Kanagawa

232-8555

Novo Nordisk Investigational Site, Kanagawa

602-8566

Novo Nordisk Investigational Site, Kyoto

371-8511

Novo Nordisk Investigational Site, Maebashi-shi, Gunma

889-1692

Novo Nordisk Investigational Site, Miyazaki

467-8602

Novo Nordisk Investigational Site, Nagoya, Aichi

951 8520

Novo Nordisk Investigational Site, Niigata-shi, Niigata

534-0021

Novo Nordisk Investigational Site, Osaka

594-1101

Novo Nordisk Investigational Site, Osaka

879-5593

Novo Nordisk Investigational Site, Ōita

336-8522

Novo Nordisk Investigational Site, Saitama-city, Saitama

330-8777

Novo Nordisk Investigational Site, Saitama-shi, Saitama

065-8611

Novo Nordisk Investigational Site, Sapporo, Hokkaido

980 8574

Novo Nordisk Investigational Site, Sendai-shi, Miyagi

431-3192

Novo Nordisk Investigational Site, Shizuoka